XENON PHARMACEUTICALS INC. Operating Cash Flow
XENON PHARMACEUTICALS INC. (XENE) reported Operating Cash Flow of -$184.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$95.39M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$88.90M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$81.48M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$71.75M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2025 was -$279.12M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2024 was -$181.39M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2023 was -$151.11M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2022 was -$101.03M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$95.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$184.29M 10-Q · filed 2026-08-06 | -$265.77M derived: sum of 3 quarters · filed 2026-08-06 | -$337.52M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$88.90M 10-Q · filed 2026-05-07 | -$170.38M derived: sum of 2 quarters · filed 2026-05-07 | -$242.13M derived: sum of 3 quarters · filed 2026-05-07 | -$306.36M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$81.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$153.23M derived: sum of 2 quarters · filed 2026-02-26 | -$217.47M derived: sum of 3 quarters · filed 2026-08-06 | -$279.12M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$71.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$135.99M derived: sum of 2 quarters · filed 2026-08-06 | -$197.64M 10-Q · filed 2025-11-03 | -$252.02M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$64.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$125.89M 10-Q · filed 2026-08-06 | -$180.27M derived: sum of 3 quarters · filed 2026-08-06 | -$229.94M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$61.65M 10-Q · filed 2026-05-07 | -$116.04M derived: sum of 2 quarters · filed 2026-05-07 | -$165.70M derived: sum of 3 quarters · filed 2026-05-07 | -$196.85M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$54.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$104.05M derived: sum of 2 quarters · filed 2026-02-26 | -$135.20M derived: sum of 3 quarters · filed 2026-02-26 | -$181.39M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$49.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$80.82M derived: sum of 2 quarters · filed 2025-11-03 | -$127.00M 10-Q · filed 2025-11-03 | -$162.41M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | -$31.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$77.34M 10-Q · filed 2025-08-11 | -$75.86M 10-Q · filed 2024-08-08 | -$112.74M derived: sum of 3 quarters · filed 2026-02-26 | -$160.82M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | -$46.19M 10-Q · filed 2025-05-12 | -$43.18M 10-Q · filed 2024-05-09 | -$81.59M derived: sum of 2 quarters · filed 2026-02-26 | -$129.67M derived: sum of 3 quarters · filed 2026-02-26 | -$162.89M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | -$35.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$83.48M derived: sum of 2 quarters · filed 2026-02-26 | -$116.70M derived: sum of 3 quarters · filed 2026-02-26 | -$151.11M 10-K · filed 2026-02-26 | -$145.33M 10-K · filed 2024-02-29 | |||
| 2023-09-30 | -$48.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$81.30M derived: sum of 2 quarters · filed 2024-11-12 | -$115.71M 10-Q · filed 2024-11-12 | -$109.86M 10-Q · filed 2023-11-08 | -$151.04M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | -$33.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$67.63M 10-Q · filed 2024-08-08 | -$102.96M derived: sum of 3 quarters · filed 2025-02-27 | -$133.36M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$34.41M 10-Q · filed 2024-05-09 | -$69.74M derived: sum of 2 quarters · filed 2025-02-27 | -$100.14M derived: sum of 3 quarters · filed 2025-02-27 | -$117.01M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$35.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$65.73M derived: sum of 2 quarters · filed 2025-02-27 | -$82.60M derived: sum of 3 quarters · filed 2025-02-27 | -$101.03M 10-K · filed 2025-02-27 | -$98.43M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | -$30.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$47.27M derived: sum of 2 quarters · filed 2023-11-08 | -$65.70M 10-Q · filed 2023-11-08 | -$86.41M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | -$16.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$35.30M 10-Q · filed 2023-08-09 | -$56.01M derived: sum of 3 quarters · filed 2024-02-29 | -$71.01M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | -$18.43M 10-Q · filed 2023-05-09 | -$39.14M derived: sum of 2 quarters · filed 2024-02-29 | -$54.15M derived: sum of 3 quarters · filed 2024-02-29 | -$67.22M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | -$20.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$35.72M derived: sum of 2 quarters · filed 2024-02-29 | -$48.79M derived: sum of 3 quarters · filed 2024-02-29 | -$69.50M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | -$15.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$28.08M derived: sum of 2 quarters · filed 2022-11-08 | -$48.79M 10-Q · filed 2022-11-08 | -$61.91M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | -$13.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$33.78M 10-Q · filed 2022-08-09 | -$46.90M derived: sum of 3 quarters · filed 2023-03-01 | -$58.05M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | -$20.71M 10-Q · filed 2022-05-10 | -$33.82M derived: sum of 2 quarters · filed 2023-03-01 | -$44.98M derived: sum of 3 quarters · filed 2023-03-01 | -$55.77M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | -$13.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$24.27M derived: sum of 2 quarters · filed 2023-03-01 | -$35.06M derived: sum of 3 quarters · filed 2023-03-01 | -$48.12M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | -$11.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$21.94M derived: sum of 2 quarters · filed 2021-11-10 | -$35.01M 10-Q · filed 2021-11-10 | -$15.22M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | -$10.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$23.86M 10-Q · filed 2021-08-11 | -$4.07M derived: sum of 3 quarters · filed 2021-08-11 | -$11.13M derived: sum of 4 quarters · filed 2021-08-11 | ||||
| 2020-03-31 | -$13.07M 10-Q · filed 2021-05-11 | $6.72M derived: sum of 2 quarters · filed 2021-05-11 | -$338.00K derived: sum of 3 quarters · filed 2021-05-11 | -$9.09M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | $19.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $12.73M derived: sum of 2 quarters · filed 2021-03-01 | $3.98M derived: sum of 3 quarters · filed 2021-03-01 | -$4.71M 10-K · filed 2021-03-01 | -$4.63M 10-K · filed 2020-03-09 | |||
| 2019-09-30 | -$7.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$15.80M derived: sum of 2 quarters · filed 2020-11-05 | -$24.50M 10-Q · filed 2020-11-05 | -$24.37M 10-Q · filed 2019-11-05 | -$31.74M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-30 | -$8.75M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2020-08-06 | -$17.44M 10-Q · filed 2020-08-06 | -$17.30M 10-Q · filed 2019-08-06 | -$24.68M derived: sum of 3 quarters · filed 2020-08-06 | -$38.41M derived: sum of 4 quarters · filed 2020-08-06 | |||
| 2019-03-31 | -$8.70M 10-Q/A · filed 2020-05-26 | -$8.67M 10-Q · filed 2019-05-07 | -$15.94M derived: sum of 2 quarters · filed 2020-05-26 | -$29.66M derived: sum of 3 quarters · filed 2020-05-26 | -$35.20M derived: sum of 4 quarters · filed 2020-05-26 | |||
| 2018-12-31 | -$7.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$20.97M derived: sum of 2 quarters · filed 2020-03-09 | -$26.50M derived: sum of 3 quarters · filed 2020-03-09 | -$34.72M 10-K · filed 2020-03-09 | ||||
| 2018-09-30 | -$13.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$19.26M derived: sum of 2 quarters · filed 2019-11-05 | -$27.48M 10-Q · filed 2019-11-05 | -$34.32M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | -$5.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$13.76M 10-Q · filed 2019-08-06 | -$20.59M derived: sum of 3 quarters · filed 2019-08-06 | -$29.22M derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2018-03-31 | -$8.22M 10-Q · filed 2019-05-07 | -$15.06M derived: sum of 2 quarters · filed 2019-05-07 | -$23.68M derived: sum of 3 quarters · filed 2019-05-07 | |||||
| 2017-12-31 | -$6.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | -$15.46M derived: sum of 2 quarters · filed 2019-03-06 | -$28.73M 10-K · filed 2019-03-06 | |||||
| 2017-09-30 | -$8.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$21.89M 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | -$13.26M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |